Cwm, LLC Eagle Pharmaceuticals, Inc. Transaction History

Cwm, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	SELL	$3.34 - $5.6 $1,887 - $3,164	-565 Reduced 25.26%	1,672 $9,000
Q1 2024 Apr 05, 2024	SELL	$4.26 - $6.51 $8,882 - $13,573	-2,085 Reduced 48.24%	2,237 $12,000
Q4 2023 Feb 01, 2024	BUY	$4.63 - $15.21 $15,084 - $49,554	3,258 Added 306.2%	4,322 $23,000
Q3 2023 Oct 11, 2023	BUY	$15.21 - $22.88 $7,361 - $11,073	484 Added 83.45%	1,064 $17,000
Q2 2023 Aug 03, 2023	BUY	$17.74 - $31.87 $8,053 - $14,468	454 Added 360.32%	580 $11,000
Q1 2023 Apr 28, 2023	SELL	$25.06 - $34.09 $2,756 - $3,749	-110 Reduced 46.61%	126 $4,000
Q4 2022 Feb 01, 2023	BUY	$24.98 - $39.77 $1,698 - $2,704	68 Added 40.48%	236 $7,000
Q3 2022 Oct 27, 2022	BUY	$26.42 - $47.12 $4,438 - $7,916	168 New	168 $4,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwm, LLC with notifications on news.